¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"dose profile"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • biologically effective dose
    »ý¹°ÇÐÀûÀ¯È¿¼±·®
  • booster dose
    1. Ãß°¡¿ë·® 2. Ãß°¡Á¢Á¾·®
  • collective effective dose
    Áý´ÜÀ¯È¿¼±·®
  • committed dose equivalent
    ¿¹Å¹¼±·®ÇØ´ç·®
  • committed effective dose
    ¿¹Å¹À¯È¿¼±·®
  • cumulative dose
    1. ´©Àû¿ë·® 2. ´©Àû¼±·®
  • curative dose
    1. Ä¡À¯¿ë·® 2. Ä¡À¯¼±·®
  • depth dose
    ½ÉºÎ¼±·®
  • depth dose curve
    ½ÉºÎ¼±·®°î¼±
  • dose
    1. ¿ë·®, Åõ¿©·® 2. ¼±·®, Á¶»ç·®
  • dose distribution
    ¹æ»ç¼±·®ºÐÆ÷
  • dose rate
    1. ¼±·®·ü 2. Åõ¿©·®
  • dose rate effect
    ¼±·®·üÈ¿°ú
  • dose rate meter
    ¼±·®·ü°è, ¼±·®·üÃøÁ¤±â
  • dose-response curve
    ¿ë·®¹ÝÀÀ°î¼±
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • booster dose
    Ãß°¡Á¢Á¾·®, Ãß°¡¿ë·®
  • collective effective dose
    Áý´ÜÀ¯È¿¼±·®
  • collective equivalent dose
    Áý´Ü´ç·®¼±·®
  • committed dose equivalent
    ¿¹Å¹¼±·®ÇØ´ç·®
  • committed effective dose
    ¿¹Å¹À¯È¿¼±·®
  • committed equivalent dose
    ¿¹Å¹´ç·®¼±·®
  • cumulative dose
    ´©Àû·®, ´©Àû¼±·®
  • curative dose
    Ä¡À¯¿ë·®, Ä¡À¯¹æ»ç¼±·®
  • depth dose curve
    ½ÉºÎ¼±·®°î¼±
  • dose-response curve
    ¿ë·®¹ÝÀÀ°î¼±
  • percentage depth dose curve
    ½ÉºÎ¼±·®¹éºÐÀ²°î¼±
  • sigmoid dose-response curve
    ±¸ºÒ¼±·®¹ÝÀÀ°î¼±
  • dose
    ¿ë·®, Åõ¿©·®, ¹æ»ç¼±·®
  • depth dose
    ½ÉºÎ¼±·®
  • dose distribution
    ¹æ»ç¼±·®ºÐÆ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • MED=> minimum effective dose
    ÃÖ¼ÒÀ¯È¿·®.
  • MED=£¾minimum effective dose
    ÃÖ¼ÒÀ¯È¿·®.
  • MTD=> maximum toderance dose
    ÃÖ´ë³»¿ë·®.
  • MTD=£¾maximum tolerance dose
    ÃÖ´ë³»¿ë·®.
  • MTD=ÊÝmaximum toderance dose
    ÃÖ´ë³»¿ë·®.
  • STD= standard test dose
    Ç¥ÁؽÃÇè·®.
  • absorbed dose
    Èí¼ö·®.¹æ»ç¼±Èí¼ö¼±·®(ýåâ¥àÊåÖ).
  • absorbed dose
    Èí¼ö¼±·®
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • absorbed dose rate
    Èí¼ö¼±·®À²
  • acceptable daily dose : ADD
    ÀÏÀÏÇã¿ë·®(ìéìíúÉé»Õá).
  • acceptable dose
    ¿ëÀμ±·®, ¼ö¿ë¼±·®, Çã¿ë¼±·®
  • adult dosage =a. dose
    ¼ºÀη®, ¼ºÀο뷮.
  • arbitrary dose
    ÀÓÀǿ뷮(ìòëòéÄåÖ).
  • fractional dose
    ºÐÇÒ·®.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • personality profile
    ÀÎ°Ý ÇÁ·ÎÇÊ
  • phospholipid profile
    ÀÎÁöÁúÇÁ·ÎÇÊ<¾ç»ó(åÆßÓ)>
  • profile plasty
    Ãø¸é¼ºÇü¼ú
  • profile to X-ray beam
    Á¾´Ü¸é, ¿·¸é
  • slice profile
    ÀýÆí Ãø¸éµµ
  • torsional profile
  • urethral pressure profile
    ¿äµµ¾ÐÃø¸éµµ
  • velocity profile
    ¼Óµµ ºÐÆ÷»ó
  • velocity profile
    ¼Óµµ ºÐÆ÷ »óÅ (áÜÓø ÝÂøÖ ßÒ÷¾)
  • velocity profile
    ¼ÓµµºÐÆ÷Çü(áÜöôÝÂøÖúþ).
  • absorbed dose
    Èí¼ö¼±·®
  • absorbed dose
    Èí¼ö·®.¹æ»ç¼±Èí¼ö¼±·®(ýåâ¥àÊåÖ).
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • absorbed dose rate
    Èí¼ö¼±·®À²
  • acceptable daily dose : ADD
    ÀÏÀÏÇã¿ë·®(ìéìíúÉé»Õá).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • median effective dose
    Á¤Áß À¯È¿·®(ïáñéêóüùÕá)
  • median hemolytic dose
    Á¤Áß ¿ëÇü·®(ïáñééÁúìÕá)
  • median immunizing dose
    Á¤Áß ¸é¿ª·®(ïáñéØóæµÕá)
  • median infectious dose
    Á¤Áß °¨¿°·®(ïáñéÊïæøÕá)
  • median lethal dose
    Á¤Áß Ä¡»ç·®(ïáñéöÈÞÝÕá)
  • median paralysis dose
    Á¤Áß ¸¶ºñ·®(ïáñ騫ÝöÕá)
  • median tissue culture dose
    Á¤ÁßÁ¶Á÷¹è¾ç·®(ïáñéðÚòÄÛÆå×Õá)
  • median toxic dose
    Á¤Áß µ¶¼º·®(ïáñéÔ¸àõÕá)
  • minimum hemagglutinating dose
    ÃÖ¼ÒÇ÷±¸ÀÀÁý·®(õÌá³úìϹëêó¢Õá)
  • minimum hemolytic dose
    ÃÖ¼Ò¿ëÇ÷·®(õÌá³éÁúìÕá)
  • minbimum lethal dose
    ÃÖ¼ÒÄ¡»ç·®(õÌá³öÈÞÝÕá)
  • permissible dose
    Çã¿ë·®(úÉé»Õá)
  • priming dose
    ÀÏÂ÷󸮿뷮(ìéó­ô¥×âéÄÕá)
  • radiation absorbed dose
    ¹æ»ç¼± Èí¼ö·®(Û¯ÞÒàÊýåâ¥Õá)
  • radiation dose
    ¹æ»ç¼±·®(Û¯ÞÒàÊÕá)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • half lethal dose
    ¹ÝÄ¡»ç·®
  • LD = lethal dose
    Ä¡»ç·®
  • lethal dose [=LD]
    Ä¡»ç·®
  • maintenance dose
    À¯Áö¿ë·®
  • maximal acceptable dose
    ÃÖ´ëÇã¿ë¼±·®
  • maximum permissible dose [=MPD]
    ÃÖ´ëÇã¿ë(¼±)·®
  • median lethal dose
    50%Ä¡»ç·®, Æò±ÕÄ¡»ç·®
  • midbreast dose
    À¯¹æÁß¾ÓÁ¶»ç¼±·®
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • permissible internal dose
    ³»ºÎÇã¿ë¼±·®
  • radiation absorbed dose
    ¶óµå, ¹æ»ç¼±Èí¼ö¼±·®
  • relative dose
    ºñ±³Á¶»ç·®, »ó´ëÁ¶»ç·®
  • single dose
    ÀÏȸ·®
  • skin dose
    ÇǺμ±·®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MD Doctor of Medicine [Lat. Medicinae Doctor]; magnesium deficiency; main duct; maintenance dose; major...
MID maximum inhibiting dilution; mesioincisodistal; midinfarct dementia; minimum infective dose; minimum...
NSD Nairobi sheep disease; neonatal staphylococcal disease; neurosecretory dysfunction; night sleep depr...
TCD tapetochoroidal dystrophy; T-cell depletion; thermal conductivity detector; tissue culture dose; tra...
AD accident dispensary; acetate dialysis; active disease; acute dermatomyositis; addict, addiction; ade...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
OHIP Oral Health Impact Profile
POMS Profile Of Mood State
SIP Sickness Impact Profile
SSP Slice sensitivity profile
UPP Urethral pressure profile
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cumulative absorbed dose
    ´©Àû ¼±·®, ´©Àû Èí¼ö¼±·®
  • cumulative dose
    ÁýÀû ¼±·®, ´©Àû Á¶»ç·®, ´©Àû ¿ë·®, Ãàô ¿ë·®
  • curative dose
    ġȿ·®
  • daily dose
    ÀÏÀÏ·®, ÀϿ뷮
  • dose calculation
    ¼±·® °è»ê
  • dose commitment
    ¼±·® ¿¹Å¹
  • dose costraint
    ¼±·® ±¸¼ÓÄ¡
  • dose equivalent
    ¼±·® ´ç·®
    ¹æ»ç¼±ÀÇ ½ÇÈ¿Àû ¼±·®. ¹æ»ç¼± ¹æÈ£ ÀÔÀå¿¡¼­ Á¾·ù³ª ¿¡³ÊÁö°¡ ´Ù¸¥ ¹æ»ç¼±ÀÌ »ýü¿¡ ¹ÌÄ¡´Â È¿°ú¿¡ ÁÖ¸ñÇÏ¿© ±Ù³â¿¡ ¿Í¼­ Á¤ÀǵǾú´Ù. ´ÜÀ§´Â remÀÌ´Ù.
  • dose limit
    ¼±·® Çѵµ, ¼±·® Á¦ÇÑ
  • dose modifying factor
    ¼±·® ¼ö½Ä °è¼ö
  • dose rate effect
    ¼±·®À² È¿°ú
  • dose rate variation
    ¼±·®·ü º¯È­
  • dose response relationship
    ¹æ»ç¿ë·® ¹ÝÀÀ °ü°è, ¿ë·® ¹ÝÀÀ °ü°è
  • dose-effect relationship
    ¼±·® ¿µÇâ °ü°è
  • dose-equivalent limit
    ¼±·® ´ç·® Çѵµ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
lipid profile Pattern of lipids in the blood. (A lipid profile usually includes the total cholesterol, high density lipoprotein (hdl) cholesterol, triglycerides, and the calculated low density lipoprotein (ldl) cholesterol.
(12 Dec 1998)
liver profile <investigation> A test that measures the blood serum level of several enzymes produced by the liver. An elevated liver function test is a sign of possible liver damage.
Examples include: prothrombin time, PTT, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, gamma glutamyl transpeptidase, alkaline phosphatase and serum albumin.
(14 Oct 1997)
Lovibond's profile sign The angle made at the meeting of the proximal nail fold and the nail plate when viewed from the radial aspect; normally, less than 180
absorbed dose The amount of energy absorbed per unit mass of irradiated material at the target site; in radiation therapy, the former unit for absorbed dose is the rad; the current (S.I.) unit is the gray.
(05 Mar 2000)
air dose The radiation dose, expressed in roentgens, delivered at a point in free air.
Synonym: air dose.
(05 Mar 2000)
bone marrow dose The cumulative dose to the blood-forming organ from therapeutic or nuclear fallout irradiation; the presumed leukemogenic dose.
(05 Mar 2000)
booster dose A dose given at some time after an initial dose to enhance the effect, said usually of antigens for the production of antibodies.
(05 Mar 2000)
breast dose in mammography <radiology> 180 mrad / view -- mid-breast dose, guideline: less than 1 rad for 2-view exam
(12 Dec 1998)
maintenance dose In chemotherapy, systematic dosage at a level that maintains protection against exacerbation.
(05 Mar 2000)
genetically significant dose <physics, radiobiology> The genetically significant dose is that which, if received by every member of the population, would be expected to produce the same genetic injury to the population as do the actual doses received by the individuals irradiated.
Thus, the genetically significant dose is the dose equivalent to the gonads weighted for the age and sex distribution in those members of the irradiated population expected to have offspring. The genetically significant dose is expressed in sieverts (or rem).
Acronym: GSD
(06 Aug 1998)
maximal dose <pharmacology> The largest amount of a drug or physical procedure that an adult can take with safety.
(05 Mar 2000)
maximum permissible dose <radiobiology> Defined by the International Commission on Radiological Protection as the greatest dose of radiation which, in the light of present knowledge, is not expected to cause detectable bodily injury to a person at any time during his lifetime.
This dose has been reduced with each Commission report. The MPD is given in terms of acute or chronic exposure of the whole body or of organs, systems, or regions of the body, and differs for persons who are occupationally exposed versus the public at large.
(05 Mar 2000)
median effective dose The dose that produces the desired effect; when followed by a subscript (generally "ED50"), it denotes the dose having such an effect on a certain percentage (e.g., 50%) of the test animals; ED50 is the median effective dose, in radiation protection, the sum of the equivalent doses in all tissues and organs of the body weighted for tissue effects of radiation. The unit of effective dose is the sievert (Sv), epilation dose, the minimum amount of radiation sufficient to produce hair loss, usually in 10 to 14 days.
(05 Mar 2000)
gonadal dose The exposure dose to the male or female gonad, usually from incidental secondary radiation in diagnostic or therapeutic irradiation, or from whole-body irradiation.
Synonym: gonadal dose.
(05 Mar 2000)
gonad dose The exposure dose to the male or female gonad, usually from incidental secondary radiation in diagnostic or therapeutic irradiation, or from whole-body irradiation.
Synonym: gonadal dose.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á